Last year, Pfizer announced preliminary results of a clinical trial for its novel COVID 19 oral antiviral drug, PAXLOVIDTM. Reductions in COVIDfQ-related hospitalization or death were observed in patients treated within five days of symptom onset. 6 out of 607 of patients who received PAXLOVID were hospitalized or died through Day 28 following randomization, compared to 6.7% of patients who received a placebo (no drug). Assume that the true hospitalizationordeath rate for the placebo group (6.7%) is known. Pfizer would like to prove that PAXLOVID provides a reduced hospitalization-ordeath rate relative to the placebo group. Use the information to answer the following duestions